Zydus Life noted that population-scale studies show high rates of bone involvement, affecting 50-70% of advanced breast or ...
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...
Cancer drug developer Immutep has landed a major offshore commercialisation deal worth $30 million upfront and as much as ...
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...
Sydney-based Immutep and Dr Reddy’s Laboratories have inked an exclusive licensing agreement through their arms for the ...
Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute ...
Citi Annual Global Healthcare Conference 2025 December 4, 2025 9:45 AM ESTCompany ParticipantsAnthony Pagano - Executive VP ...
The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...
Vietnam has approved the Russian cancer drug Pembroria, offering patients a new, cost‑effective treatment option. The move follows deeper health cooperation with Russia and comes as cancer cases in ...
Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback